40 results
8-K
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
to the satisfaction of customary closing conditions. As a result of the Offering, the Company expects its cash and cash equivalents to be sufficient to fund … to market conditions and the satisfaction of customary closing conditions related to the Offering. These and other risks and uncertainties
8-K
EX-4.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”) but did not receive within
8-K
EX-1.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative.
(b … in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”) but did not receive within
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
. The offering is expected to close on or about May 20, 2024, subject to satisfaction of customary closing conditions.
The financing was led by Dimension … , including the satisfaction of customary closing conditions related to the offering. Forward-looking statements include all statements
424B5
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Prospectus supplement for primary offering
4:04pm
to or changes in the provisions relating to satisfaction and discharge of the indenture;
additions to or changes in the provisions relating to the modification
424B5
4qzzg1z
15 May 24
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
y99pn4nn1qpdrq2
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-10.1
5mz 03fb9
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-4.1
i9dd9zayf4e3
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
424B5
2j2y5h
26 Oct 23
Prospectus supplement for primary offering
4:55pm
S-3
EX-4.6
stnp7g644gi7sicb
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.5
b6xze4q8d0fgubvl
1 Jul 22
Shelf registration
5:01pm
S-3
4u48mi
1 Jul 22
Shelf registration
5:01pm
S-3
EX-1.2
2umubv xd2ljwwcs684
1 Jul 22
Shelf registration
5:01pm
10-K
q8d6o2fm
29 Mar 22
Annual report
4:15pm
10-K
EX-10.20
hd8k1
29 Mar 22
Annual report
4:15pm
10-Q
z84l2
12 Aug 21
Quarterly report
4:22pm